News Articles

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference

SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief executive officer, Dr. Keting Chu, M.D., Ph.D., will present at the 2nd Global IR@JPM Conference on Thursday, January 20, 2022 in the biotech track to be held 7:30 - 9:30 p.m. ET.

Dr. Chu will provide an overview of the company, including BlueJay’s two therapeutic approaches with potential high rate of functional cure for HBV infections -- its best-in-class anti-HBsAg monoclonal antibody approach and novel, first-in-class HBsAg inhibitor program -- its preeminent management team with a proven track record in anti-infectives, strong patent position and backing by top healthcare investors.

To access the live webcast, please visit   

Read Full Article
2022 Global IR

2022 Global IR @ JPM Virtual Demo Day Tickets, Wed, Jan 19, 2022 at 7:00 PM | Eventbrite

Bluejay Therapeutics will present in the 2nd annual Global IR @ JPM (Jan. 19-20 EST).

Bluejay Therapeutics' presentation would be delivered live, via Zoom, as part of our Day 2 Global Biotech track (7:30-9:30 p.m. EST on Jan. 20).

Since 1993, BioCentury Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.    Register

Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection

Basel, Switzerland, 17 November 2021 - BlueJay, a developer of innovative therapeutics for functional cures of chronic hepatitis B virus (HBV) infection, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a manufacturing agreement for BJT-778, one of BlueJay's lead candidates. This monoclonal antibody (mAb), targeting the HBV surface antigen (HBsAg), is currently under preclinical development for the restoration of patient's adaptive immunity and functional cure for chronic HBV infection.    Read Full Article


Bluejay is applying a combination of therapies in-licensed from Novartis with an aim to cure chronic HBV by reducing viral surface antigen in both the liver and blood.

Founder, Chairman and CEO Keting Chu said she had been interested in building a company around HBV assets from Novartis AG (NYSE:NVS; SIX:NOVN) after the pharma exited infectious disease in 2018. A Novartis alum herself, Chu met Novartis Institutes for BioMedical Research’s Jennifer Leeds at a California Life Sciences Institute meeting a few years ago; the connection set the stage for an in-licensing deal. Leeds is executive director and head of BD&L search and evaluation, West Coast and Canada.

Chu said she believed in the assets, knowing that NIBR’s Donald Ganem was involved in their discovery and early development. Ganem, who was VP and head of global infectious diseases research at NIBR in 2011-18, is a professor emeritus of microbiology and immunology at University of California San Francisco, where Chu attended graduate school.

Chu launched Bluejay Therapeutics Inc. in 2019 with exclusive global rights to three of the pharma’s therapies: BJT-778, a mAb against HBV surface antigen (HBsAg); BJT-574, a small molecule HBsAg inhibitor; and a small molecule capsid inhibitor.

Most recently a Lyfe Capital partner, Chu has led multiple start-ups in addition to holding research and executive roles at The Leukemia & Lymphoma Society, Five Prime Therapeutics Inc., Chiron Corp. and Novartis.    Read Full Article